JP2004529108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529108A5 JP2004529108A5 JP2002569154A JP2002569154A JP2004529108A5 JP 2004529108 A5 JP2004529108 A5 JP 2004529108A5 JP 2002569154 A JP2002569154 A JP 2002569154A JP 2002569154 A JP2002569154 A JP 2002569154A JP 2004529108 A5 JP2004529108 A5 JP 2004529108A5
- Authority
- JP
- Japan
- Prior art keywords
- physiologically acceptable
- acceptable salt
- salmeterol
- pharmaceutical
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 7
- 229960000289 fluticasone propionate Drugs 0.000 claims 4
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229960004017 salmeterol Drugs 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 1
- 230000005465 channeling Effects 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960005018 salmeterol xinafoate Drugs 0.000 claims 1
- 229950000339 xinafoate Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105560.7A GB0105560D0 (en) | 2001-03-07 | 2001-03-07 | Pharmaceutical formulations |
| PCT/GB2002/000909 WO2002069979A2 (en) | 2001-03-07 | 2002-03-04 | Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529108A JP2004529108A (ja) | 2004-09-24 |
| JP2004529108A5 true JP2004529108A5 (https=) | 2005-12-22 |
Family
ID=9910112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569154A Pending JP2004529108A (ja) | 2001-03-07 | 2002-03-04 | Ｒ−サルメテロールおよびプロピオン酸フルチカゾンを含んでなる医薬製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040136918A1 (https=) |
| EP (1) | EP1365767A2 (https=) |
| JP (1) | JP2004529108A (https=) |
| AU (1) | AU2002237400A1 (https=) |
| GB (1) | GB0105560D0 (https=) |
| WO (1) | WO2002069979A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| US20080190418A1 (en) * | 2003-08-29 | 2008-08-14 | Glaxo Group Limited | Pharmaceutical Metered Dose Inhaler and Methods Relating Thereto |
| EA200700600A1 (ru) * | 2004-09-09 | 2008-02-28 | Сипла Лимитед | Фармацевтическая композиция, содержащая изомер бета-миметического агента и антихолинергический агент |
| US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| DK2377557T3 (en) | 2004-11-24 | 2017-02-06 | Meda Pharmaceuticals Inc | Compositions comprising azelastine and methods for its use |
| US20070020330A1 (en) * | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US8415390B2 (en) * | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US9119777B2 (en) * | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| TR201000685A2 (tr) * | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Salmeterol ve flutikazon içeren farmasötik preparatlar. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ235605A (en) * | 1989-10-10 | 1992-12-23 | Glaxo Group Ltd | (r)-(-)-4-hydroxy-alpha 1 -(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol and pharmaceutical compositions |
| US5919827A (en) * | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol |
| MX9707864A (es) * | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Inhalador de dosis medida por salmeterol. |
| MX9707862A (es) * | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Inhalador de dosis medida para el propionato de fluticasona. |
| US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
| ES2238334T3 (es) * | 1999-12-24 | 2005-09-01 | Glaxo Group Limited | Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona. |
-
2001
- 2001-03-07 GB GBGB0105560.7A patent/GB0105560D0/en not_active Ceased
-
2002
- 2002-03-04 WO PCT/GB2002/000909 patent/WO2002069979A2/en not_active Ceased
- 2002-03-04 JP JP2002569154A patent/JP2004529108A/ja active Pending
- 2002-03-04 EP EP02703715A patent/EP1365767A2/en not_active Withdrawn
- 2002-03-04 AU AU2002237400A patent/AU2002237400A1/en not_active Abandoned
- 2002-03-04 US US10/469,945 patent/US20040136918A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| RU98118908A (ru) | Баллон для доставки фармацевтического состава, дозирующий ингалятор | |
| GR3018168T3 (en) | Medicaments. | |
| RU2010108640A (ru) | Новая комбинация терапевтических агентов | |
| JP2016040316A5 (https=) | ||
| RU2001126347A (ru) | Композиции, включающие формотерол и фуроат мометасона, предназначенные для лечения астмы | |
| CA2447510A1 (en) | Fluorocarbon aerosol medicaments | |
| DE69936730D1 (de) | Pharmazeutische aerosolzubereitung, die hfa227 und hfa 134a enthält | |
| ATE308317T1 (de) | Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung | |
| JP2003518484A5 (https=) | ||
| JP2004529108A5 (https=) | ||
| HRP20140550T1 (hr) | Aerosolna formulacija za copd | |
| JP2005508963A5 (https=) | ||
| NZ600208A (en) | Inhalation solutions | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| US20130104881A1 (en) | Stabilized Metered Dose Inhaler | |
| JP2005514440A (ja) | アミドおよび／またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物 | |
| RU2020112519A (ru) | Ингалятор и сетка для ингалятора | |
| ES2259915B1 (es) | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. | |
| US20230057979A1 (en) | Medicinal compositions for carbon dioxide based metered dose inhalers | |
| JP2006508993A5 (https=) | ||
| WO2004103339A3 (en) | Improved metered dose inhaler | |
| Linne-Geyer et al. | P291 In-use stability of aclidinium bromide 400 μg/formoterol fumarate dihydrate 12 μg inhalation powder in a dry powder inhaler | |
| CA2456721A1 (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders |